Carfilzomib given at a higher dose as a slow intravenous infusion over 30 minutes resulted in a very high response rate in a heavily pretreated myeloma population.

Treatment of relapsed or refractory multiple myeloma with the three-drug combination of panobinostat/bortezomib/dexamethasone resulted in a nearly 4-month improvement in progression-free survival compared to treatment with bortezomib/dexamethasone alone.

Continuous therapy produces drastically better progression-free survival and overall survival outcomes in patients with multiple myeloma. A novel endpoint involving time to second progression is an important tool in evaluating this type of treatment in the future.